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Abstract The most demanding patient population on
peritoneal dialysis (PD) consists of children under 2 years
of age. Their growth is inferior to that of older children and
maintaining euvolemia is difficult, especially in anuric
patients. In this prospective study reported here, we
enrolled 21 patients <2 years of age (mean 0.59 years) at
onset of PD and monitored their uremia parameters and
evaluated their nutrition. Since no good instrument current-
ly exists for estimating intravascular volume status, we used
traditional blood pressure measurements, echocardiography,
and N-terminal atrial natriuretic peptide measurements.
Growth was compared with midparental height. Metabolic
control was good. Long-term hypertension was seen in 43%
of the patients, but left ventricular hypertrophy decreased
during the study period. Mean weekly urea Kt/V was 3.38±
0.66 and creatinine clearance was 49±20 L/week per
1.73 m2. Catch-up growth was documented in 57% of the
patients during PD. However, these children did not attain
their midparental height at the end of PD at a mean age of
1.71 years. Although favorable metabolic control and good
growth were achieved during PD, these children lagged in
term of their midparental height. We conclude that several
instruments are needed for determining the management of
intravascular volume status and that the control of calcium–
phosphorus status is demanding.
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Introduction
Doubts were expressed for many years on whether infants
and small children should be treated with peritoneal dialysis
(PD), and not all centers offered this treatment possibility
[1–4]. Currently, PD is widely used and technically feasible
due to good surgical techniques, small catheters and
tubings, and the development of special dialysis machines
and programs for patients in this age group. However,
hypervolemia-associated problems, such as hypertension
and cardiac hypertrophy, are still major concerns [5]. In
addition, although growth is “normal for age” [6, 7], it may
not correspond to the target height of the child.
The dialysis period has been found to be the most critical
time in terms of the potential for the development of
complications, leading to life-long disabilities in small
children with end-stage renal failure. For example, hemo-
dynamic crises may lead to serious sequelae [8]. Clinical
status and blood pressure measurements do not provide
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sufficient information for a precise estimation of the
intravascular volume status. However, in a study on Finnish
patients, Hölttä et al. showed that pulmonary edema- and
hypervolemia-associated seizures could be avoided in small
children on PD [6, 9], although hypertension and the need
for antihypertensive medication were still common in
infants, especially if nephrectomized [6]. On the other
hand, hypovolemia and severe hypotension may cause
brain damage and visual disability [7, 10]. Left ventricular
hypertrophy (LVH) is considered to be an important marker
of cardiovascular disease [11] and has been detected in 60%
of PD patients under 5 years of age [5]. Yet defining left
ventricular mass (LVM) and LVH is not clear and absolute
[11], and small children constitute a special challenge [12].
These issues should be further evaluated.
In a prior retrospective analysis of the growth of infants
on PD, we noted that the infants on PD had an average
weekly urea Kt/V > 3 and a creatinine clearance (Ccr) of
>70 L/week per 1.73 m2 [6]. These are clearly higher than
the adult targets for PD, which are a weekly urea Kt/V≥2.1
and Ccr≥63 L/week per 1.73 m2 [13]. However, these
results overestimate the clearances by up to 15% due to the
dialysate and urine collection method [6].
To further maximize growth and development in this age
group, we initiated a study emphasizing these problems. Here,
we report on the nutrition, metabolic control, solute clear-
ances, intravascular volume status, heart measures, and
growth compared with midparental height in 21 prospectively
followed infants treated by the same PD protocol since 2001.
Neurological and psychosocial development of these infants
will be presented in detail in a subsequent report.
Materials and methods
Patients
All children <2 years of age at onset of PD who were
treated at our institution between 2001 and 2005 were
enrolled in this prospective study (n=21). The clinical
characteristics of the patients are presented in Table 1.
Bilateral nephrectomy was performed in 17 infants (81%).
Follow-up
The initiation of all chronic PD treatments as well as family
training were performed in the Hospital for Children and
Adolescents in Helsinki. Registered nurses began home
visits during the family training period to support the family
in implementing PD in the home situation. The children
visited our pediatric nephrology ward 1 and 3 months after
the initiation of PD and every third month thereafter.
Laboratory tests, growth measurements, 24-h dialysate, and
urine collection for clearances, intraperitoneal pressure
(IPP) measurements, blood pressure, and heart ultrasound
were performed during the visits. The families also met
regularly with our dietician. Follow-up at local hospitals
occurred every 1–3 weeks. This study terminated at renal
transplantation or if the patient was permanently transferred
to hemodialysis (HD).
Dialysis
The same two urologists inserted all dialysis catheters
2 weeks before nephrectomy and dialysis initiation. In two
children dialysis had to be initiated a few days after catheter
insertion. We used the Tenkhoff curled 1-cuff catheter. The
exit site was in the lateral position with the head of the
catheter oriented upwards. The fill volume was 800 mL/m2
of body surface area (BSA) in children <1 year of age and
1000 mL/m2 of BSA in older children.
The IPP was measured with a technique described by
Durand et al. [14] and applied to children by Fischbach et
al. [15, 16]. It was targeted to remain under 10 cm of water
in children <2 years of age and <16 cm of water in older
patients. The upper limit of IPP was lower in younger
children because high pressure exposes the patient to
discomfort, vomiting, and hernias, which already were
frequent problems in these patients.
Continuous cycling peritoneal dialysis (CCPD) was the
first choice of modality. Nightly dialysis treatment time was
10–11 h, including 12–14 exchanges and the last fill of
50% of the nightly dwell volume. Children with outflow
pain or ultrafiltration problems were switched to tidal
peritoneal dialysis (TPD). TPD was also used in some
infants to obtain better clearance. The treatment time on
TPD was also 10–11 h per night, and 22–26 exchanges
were performed with 50% fluid exchange per cycle. One
full outflow was performed in the middle of the program
for safety reasons, i.e. to avoid excess of fill. In nephrec-
tomized patients, two daytime dialysate exchanges, with a
volume of about 50% of the nightly dwell volume, were
performed in the afternoon to avoid hypervolemia. All
patients used the Baxter Home Choice cycler PD machine
(Baxter Healthcare Corp, Deerfield, IL). The dialysis
solution was pH-neutral bicarbonate–lactate-buffered dex-
trose solution (Physioneal; Baxter Healthcare Corp). All
dextrose concentrations were used, and weight limits were
used to determine the glucose concentration needed for
night and daytime exchanges [9]. Nightly PD was usually
performed with a mixture of low- and medium-glucose
concentration fluids, while mostly medium- and high-
glucose concentrations were used in daytime exchanges to
obtain better ultrafiltration with smaller fill volumes.
After every 24-h dialysate (and urine) collection, the
patient’s dialysis program was individually planned and
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altered according to the general condition and metabolic
balance as determined using the PD Adequest 2.0 computer
program (Baxter Healthcare). The dialysis program could
be carried out during daily routine using clearance values
for weekly urea Kt/V and Ccr that were nearest to our goals
(see laboratory values and solute clearance). This program
was originally planned for 3 months; however, the dialysate
volume was increased between visits to the clinic as the
patient grew and if metabolic control values, such as blood,
urea, nitrogen, and plasma phosphate, were deteriorating
and the preceding IPP was lower than our upper limit.
Nutrition
Nutrition was planned at initiation of PD and evaluated
monthly or, if needed, even weekly by the same dietician.
The energy provided was 80–90 kcal/kg per day, and the
amount of protein provided was 2.0–2.5 g/kg per day [17],
depending on the growth velocity of the patient. Sixteen
patients needed permanent nasogastric tubes, and one
patient needed a gastrostomy to ensure adequate energy
intake. Food intake was calculated from 2-day food records
(n=42, 14 patients), and the energy, protein, and nutrient
measures in the diet were counted with the Aivo2000–
Diet32 program, ver. 1.4.4.1 (Aivo Finland Oy, Turku,
Finland). The diet consisted of infant milk and cereal
products with energy supplements [6]. Additional energy
from dialysis solutions (glucose) was estimated to be
approximately 10 kcal/kg per day and was not included in
the nutrition analyses. Metabolic control was considered to
be favorable, with normal growth for age and internation-
ally accepted plasma creatinine and blood urea nitrogen
concentrations, with hemoglobin and pH normal for age.
Medication
All patients received regular medication for their end-stage
renal failure. Subcutaneous erythropoietin and oral iron
supplementation were given to achieve a hemoglobin
concentration of at least the minimum age-related reference
Table 1 Clinical characteristics of the patient cohorta (n=21)
Patient
no.
Sex Diagnosis Nephrectomy
(none/bilateral)
PD start
age (years)
PD duration
(years)
Peritonitis
number
Exit site and
tunnel
information
Catheter
complications
PD ended in
1 M CNF Bilateral 0.4 0.7 – – No Tx
2 F CNF Bilateral 0.4 1.9 3 1 Yes Tx
3 M CNF Bilateral 0.5 0.6 – – Yes Tx
4 M CNF Bilateral 0.5 0.6 – – Yes Tx
5 M CNF Bilateral 0.5 1.1 – 1 No Tx
6 M CNF Bilateral 0.5 0.5 – 1 Yes Exitus
7 M CNF Bilateral 0.6 1.2 – 1 Yes Tx
8 F CNF Bilateral 0.6 1.5 – 2 Yes Tx
9 M CNF Bilateral 0.7 0.6 – 1 No Tx
10 F CNF Bilateral 0.7 1.0 – 1 No Tx
11 F CNF Bilateral 0.7 1.1 3 – No Tx
12 M CNF Bilateral 0.8 0.9 – – No Tx
13 M CNF Bilateral 0.8 1.6 – 1 No Tx
14 F CNF Bilateral 1.0 0.9 3 – Yes HD
15 M CNF Bilateral 1.1 0.9 1 1 No Tx
16 F ARPKD Bilateral 0.0 0.5 1 1 Yes HD
17 F Midaortic disease Bilateral 1.3 2.3 3 1 No HD
18 F Multicystic kidney
dysplasia
None 0.0 2.5 1 1 Yes Tx
19 M Urethral valve None 0.0 1.0 1 – No Tx
20 M Hypoxemic renal injury None 0.4 1.5 – – No Tx
21 F Townes-Brocks
syndrome
None 0.7 0.9 – – No Tx
M, Male; F, female; CNF, congenital nephrotic syndrome of the Finnish type; ARPKD, autosomal recessive polycystic kidney disease; PD
peritoneal dialysis; Tx, renal transplantation; HD, transferred permanently to hemodialysis
a All patients were <2 years of age at initiation of PD. Mean age at initiation of PD was 0.59 years, mean duration of PD was 1.13 years, and peritonitis rate
was one episode per 17.8 patient-months
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values (100–120 g/L). Calcium carbonate was given as a
calcium supplement and a phosphate binder, and alphacal-
cidol as a vitamin D substitute, aiming at an intact
parathyroid hormone (iPTH) level of high normal to
twofold the upper limit of normal (50–100 ng/L). Alpha-
calcidol was given daily in the beginning and switched to
pulse therapy (three times per week) if the iPTH level
increased rapidly to >400 ng/L and the ionized-calcium
phosphate product (ion-Ca × Pi) was >2.5 mmol2/L2 [18,
19]. All patients received a multivitamin formula planned
for uremic patients. No patient received growth hormone
therapy.
Laboratory values and solute clearances
Specimens for laboratory tests were drawn at every visit to
our hospital and to local hospitals (every 1–2 weeks).
Serum ferritin was targeted to be >100 μg/L and saturated
transferrin >20%.
A 24-h dialysate collection was performed with the
patient’s normal dialysis prescription. We aimed at a
weekly urea Kt/V > 3.0 and a Ccr level >65 L/week per
1.73 m2. The clearances were calculated with the PD
Adequest 2.0 computer program (Baxter Healthcare). A
normalized protein catabolic rate (nPCR), representing each
patient’s nutritional protein status, was obtained from the
PD Adequest 2.0 program.
Intravascular volume status, hypertension, and heart
measures
For the intravascular volume status estimation, we used the
mean blood pressure of measurements taken at 2-h intervals
(with an oscillometric device) during a 24-h period, weight,
plasma N-terminal atrial natriuretic peptide (ANP-N), and
echocardiography evaluation. All tests were performed
within a 24-h period.
Hypertension was defined according to the Second Task
Force reference values for diastolic and systolic daytime
blood pressure. Hypertension was indicated if the mean
diastolic or systolic blood pressure exceeded the 95th
percentile for age and gender [20]. The patient was
considered to have hypervolemia if there was hypertension
(especially in anuric patients), the clinical status showed
overload, and the ANP-N exceeded 3 nmol/L, in accor-
dance with our previous results [5].
The echocardiography examinations were performed by
one cardiologist (J-M.H.). The echocardiographic data
consisted of a left ventricular end-diastolic dimension
(LVEDD), left ventricular end-systolic dimension
(LVESD), interventricular septal dimension at end-diastole
(SeptD), left ventricular posterior wall thickness at end-
diastole (LVPWD), and ejection fraction (EF). The refer-
ence values for the linear dimensions (LVEDD, LVESD,
SeptD, LVPWD) were calculated according to Lester et al.
[21] whose equations on their study population of infants
and small children took race, age, gender, height, weight,
and heart rate (HR) into account. We also determined LVM
using M-mode echocardiography and the Devereux formula
[22]. The LVM data were analyzed according to Foster et
al. [12] using a novel method of expressing LVM related to
body size that gives an LV mass-for-height Z-score, thus
taking smaller children better into account. The 95th
percentile was chosen as the cutoff point for LVH. The Z-
scores of the LV mass-for-height and heart dimensions were
used for the correlation analyses. The LVM was also related
to body height2.7, according to Simone et al. [23], to obtain
a linear relationship and allow comparisons to be made and
is here referred to as the left ventricular mass index
(LVMI). LVH was considered if the LVMI exceeded the
95th percentile of the age group and gender [23].
Growth
Birth length (n=18) and other height values are given as
mean height standard deviation scores (ht SDS). Growth
was reported 6 and 3 months before PD onset, if possible at
baseline, and every 3 months thereafter. Growth is
considered to be favorable, if the growth velocity is normal
for age (ht SDS change ≥ 0 during the study period). Bone
age (BA) X-rays were taken at baseline and every 6 months
thereafter. These were evaluated by one radiologist (E.M.)
according to the Greulich–Pyle method which relates them
to bone maturation in healthy Finnish children [24]. The
BA data were lacking in seven patients at baseline and in
six patients after 6 months. The parental target height
(midparental height) was calculated using parental height
measures according to Sorva et al. [25]. In evaluating
growth, the patients’ decimal ages were corrected according
to the expected date of delivery.
Statistical analyses
The statistical analyses were performed using SPSS ver.
13.0 for Windows (SPSS, Chicago, IL). The values are
expressed as the mean ± 1 SD (standard deviation) unless
otherwise stated. The growth, laboratory values, and
weekly urea Kt/V and Ccr were analyzed with the analysis
of variance (ANOVA) and Student’s t test, and comparisons
with parent-specific height were performed using the
Wilcoxon signed ranks test. The Friedman test with the
Dunn test was used for comparing heart measures,
clearances, and other laboratory values over time. Pearson’s
correlation coefficient was used for simple correlations,
such as correlating intravascular volume status indicators at
each time point, and Spearman’s correlation was used for
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nonnormally distributed data. Statistical significance was
defined as P<0.05.
This study was approved by the Ethics Committee for
Pediatrics, Adolescent Medicine and Psychiatry at the
University of Helsinki. Written informed consent was
obtained from the parents of the patients after explaining
the aim and the implementation of the study.
Results
Dialysis
The mean age at PD initiation was 0.59±0.33 years, and
mean duration of PD 1.13±0.57 years (Table 1). The total
time these patients were on PD was thus 284 months,
including 174 months (61%) on CCPD and 106 months
(38%) on TPD. Two patients needed HD (total time
3 months, 1%) between PD periods. The mean waiting
time for a kidney transplant from a deceased donor after the
patient was put on the waiting list was 5.5±4.4 months,
resulting in a mean follow-up period of 13.6 months for
growth evaluation on PD. The mean age at the end of the
follow-up was 1.71±0.68 years.
These children spent 65 days per patient-year in hospital
after the initiation of dialysis. These 65 days were broken up
into PD introduction, training of the family, and PD controls
(46%), complications of PD (28%), other infections, oper-
ations, and investigations (18%), and social causes (8%).
One patient (5%) died during PD of pneumonia after a
complication from the anesthesia; other complications are
presented in Table 1.
Nutrition and calcium–phosphate balance
The energy supply according to the 2-day food records was
84±22 kcal/kg per day, corresponding to 100±26% of the
recommended dietary allowance (RDA). The RDA of
energy was chosen according to the highest value of each
age group [26, 27]. The protein intake was 2.3±0.6 g/kg
per day, corresponding to 181±50% of the safe level of
supply (minimum) for each age group (safe levels 1.09–
1.86 g/kg per day) [28]. The vitamin supply was in the
range of the RDA.
The mean alphacalcidol dose at 6 months was 0.34±
0.35 μg/kg per week, and the mean calcium dose was 37±
30mg/kg per day. At the beginning of treatment, alphacalcidol
was given daily to 20 patients, with one patient receiving pulse
therapy. After 3 months, 12 patients received daily dosages,
seven received pulse therapy, and two had pauses in
medication due to low iPTH values. After 6, 9, and 12 months
these numbers were 13 daily/6 pulse/2 pause, 11 daily/4 pulse/
0 pause, and 4 daily/5 pulse/0 pause, respectively.
The ion-Ca × Pi level exceeded 2.5 mmol2/L2 in 48% of the
patients at baseline and in 43, 28, and 33% of the patients
after 3, 6, and 9 months on PD, respectively. The iPTH values
rose with time, mostly caused by the uremia that developed in
patients with the congenital nephrotic syndrome of the Finnish
type (NPHS1) after nephrectomy prior to dialysis, and 70%
had a value < 300 ng/L at 12 months (30%<100 ng/L).
Alkaline phosphatase level was normal in our patients.
Metabolic control and solute clearances
The laboratory values during the first 9 months are given in
Table 2. Since the patients lost sodium in their dialysate, with
a mean loss of 30 mmol per day, they needed sodium chloride
supplementation (n=19) to maintain their plasma sodium
concentration in the low–normal range (>135 mmol/L). If the
patient was hypertensive or hypervolemic, the sodium
concentrate was withdrawn from the medication.
We performed a total of ninety 24-h dialysate and urine (if
not anuric) collections and clearance studies in our patients.
The meanweekly urea Kt/Vand Ccr were 3.38±0.66 and 49±
20 L/week per 1.73 m2, respectively (Table 2). The urea Kt/
V of patients with residual renal function (RRF) (3.52±0.85)
was not significantly higher than that of anuric children
(3.32±0.59). The Ccr levels were significantly better in RRF
patients than in anuric patients: 66±27 vs. 44±13 L/week
per 1.73 m2, respectively (P<0.001). However, the number
of patients was too small for definitive conclusions to be
drawn. Although plasma creatinine increased with time,
especially in nephrectomized patients, the Ccr levels
remained stable (Table 2).
Intravascular volume status, hypertension, and heart
measures
Hypertension was detected in eight patients (40%) at
initiation of PD and in six (29%) at 3 months, seven
(37%) at 6 months, four (44%) at 9 months, and four (57%)
at 12 months on PD. All patients with diagnosed hyperten-
sion were anuric. Nine patients (43%) had longer hyper-
tensive periods that lasted at least 3 months (Fig. 1).
Seven patients (33%) received antihypertensive medica-
tion for at least 2 weeks during PD (Fig. 1). All but the
patient with fibromuscular dysplasia needed only one
antihypertensive drug to control blood pressure. We usually
used calcium-channel blockers (felodipine or nifedipine),
but the beta blocker metoprolol was also administered.
The mean plasma ANP-N values and blood pressures are
given in Table 3. After 3 months on PD, when the patients
were stable, high plasma ANP-N levels (n=19) correlated
well with both systolic and diastolic hypertension (r=0.59,
P=0.007 and r=0.57, P=0.011), respectively. Good corre-
lations were also seen at baseline and after 6 months on PD.
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The heart dimension and LV mass-for-height Z-scores
are presented in Table 3. LVH (Z-scores, n=19) correlated
well with both systolic and diastolic hypertension (r=0.67,
P=0.002 and r=0.54, P=0.017, respectively), but not with
the plasma ANP-N of patients on PD for 3 months. LVEDD
and systolic hypertension (n=15) also showed good
correlation at 3 months (r= 0.62, P=0.013). All of these
correlations and the same order of magnitude were also
seen at initiation of PD and at 6 months. The LVEDD
decreased significantly between baseline and 3 months (P=
0.002) and between baseline and 6 months (P=0.024). The
mean LVMI of patients was 105±30 g/m2.7 (LVH in 86%
of the patients) at baseline, 84±32 g/m2.7 (LVH in 63%)
after 3 months on PD, and 78±24 g/m2.7 (LVH in 35%) after
6 months on PD. Based on these assessment methods (LV
mass-for-height and LVMI), the proportion of children with
LVH decreased during PD, and this improvement was
statistically significant for both LV mass-for-height Z-scores
(P=0.016, PD start vs. 3 months; P=0.035, PD start vs.
6 months) and LVMI (P=0.027, 3 vs. 6 months on PD; P=
0.006, PD start vs. 6 months). The mean EF in our patients
was normal: 58.9±8.4% at baseline, 60.4±9.7% after
3 months on PD, and 62.1±8.2% after 6 months on PD.
Growth
In this cohort of infants, there was a decrease in themean height
standard deviation score (SDS) from birth to their initiation to
dialysis. At birth, the mean ht SDS (n=18) was −0.69±1.54
and at PD initiation, it was −1.29±1.20. After dialysis
initiation and the regular routine of standardized care, we
observed a significant increase in mean ht SDS. At 6 months
on PD, the mean ht SDS (n=18) was −1.02±0.98. Fifteen
patients were dialyzed at least 9 months, and their mean ht
Fig. 1 Long-term hypertension (duration at least 3 months) and
antihypertensive medication in 21 infants during peritoneal dialysis (PD)
Table 2 Laboratory values for the 21 patients <2 years of age on PD
Laboratory parameters Time on PD Reference values
Baseline (n=21) 3 months (n=21) 6 months (n=18) 9 months (n=9)
BUN (mmol/L) 33.5±10.2 37.7±7.7 35.2±7.2 39.9±5.5 4–14
Creatinine (μmol/L) 344±88 428±111 473±138 516±147 0–60
Hemoglobin (g/L) 103±11 120±15 112±14 124±22 111–142
Bicarbonate (mmol/L) 25±3 25±3 27±4 26±3 22–26
Ionized calcium (mmol/L) 1.28±0.08 1.29±0.07 1.26±0.07 1.28±0.06 1.17–1.35
Phosphate (mmol/L) 1.92±0.61 1.84±0.44 1.66±0.37 1.97±0.31 1.3–2.2
Alkaline phosphatase (U/L) 439±189 870±342 852±487 745±420 250–850
Intact PTH median (range) (ng/L) 58 (8–106) 145 (7–1431) 218 (24–863) 229 (24–705) 8–73
Prealbumin (mg/L) 319±125 319±58 341 ± 67 320±48 95–280
Triglycerides (mmol/L) 3.47±1.97 2.99±1.34 2.79±1.5 2.6±0.8 0.34–1.24
Total cholesterol (mmol/L) 4.9±1.8 5.2±1.7 5.5±1.5 5.1±0.8 2–5.6
HDL-cholesterol (mmol/L) 1.05±0.44 1.28±0.26 1.27±0.29 1.36±0.21 0.91–2.12
Creatinine clearance (L/week/1.73 m2) – 48.8±19.1 49.3±18.1 48.8±29.7
Weekly urea Kt/V – 3.34±0.79 3.46±0.56 3.49±0.78
Protein catabolic rate (g/kg per day) – 3.52±0.57 3.22±0.52 3.22±0.40
All values are the mean ± 1 SD (standard deviation)
BUN, Blood urea nitrogen; PTH, parathyroid hormone; HDL, high-density lipoprotein
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SDS was −1.59±1.19 at initiation and −1.19±1.25 after
9 months. These differences were not statistically significant.
However, when the whole dialysis period in all patients was
considered, the mean ht SDS scores were −1.29±1.20 and
−0.86±0.99 (P=0.036) at onset and at the end of PD,
respectively. Individual growth curves are given in Fig. 2.
Catch-up growth was documented in 12 patients (57%)
during PD.
At baseline, the mean BA was 0.62±0.35 years com-
pared with the mean decimal age of 0.67±0.25 years; the
correlation was favorable (r=0.74, P=0.003). After
6 months, the mean BA was 1.19±0.34 years, with a mean
decimal age of 1.20±0.27 years, and the correlation was
moderate (r=0.53, P=0.043).
Although these children grew well during dialysis, their
height lagged significantly compared with their parental
target ht SDS during dialysis and at the end of PD at a
mean age of 1.71 years (P<0.01 at initiation of PD,
6 months on PD, and at the end) (Fig. 3).
Discussion
The results of our prospective study show that it is possible
to maintain favorable metabolic control and ensure normal
growth in infants during PD. However, the children
enrolled in our study were still significantly smaller than
their parental target height predicted at the end of infancy.
In addition, problems remained in treating hyperparathy-
roidism and hypertension, while hypervolemia stressed the
heart in many patients.
Nutrition and metabolic balance were favorable among
our patients, but protein intake was much higher than
recommended in the newest Kidney Disease Outcomes
Quality Initiative (KDOQI) guidelines. Our patients
received 2.3±0.6 g/kg protein per day compared with
recent recommendations of 1.5–1.8 g/kg per day for
children <1 year of age and 1.3 g/kg per day for children
between 1 and 3 years [29]. The more protein in the diet,
the more phosphorus the patient receives, which in turn
increases the requirement for phosphate binders, which
currently are mostly calcium-based. Thus, >40% of our
patients had an ion-Ca × Pi that was higher than
recommended. Most of our patients were in a state of
protein malnutrition at the initiation of PD due to protein
losses before nephrectomy in the NPHS1 patients. Al-
though these patients needed protein substitution at PD
initiation, their protein intake should probably have been
reduced after a few months on PD to avoid excess
calcium.
Table 3 Linear heart dimensions and LV mass-for-height Z-scores and the percentage of patients exceeding the 95th percentile in 21 patients
<2 years of age at onset of PD
Measures PD duration
Baseline (n=16) 3 months (n=15) 6 months (n=17)
Z-score Proportion >95th
percentile
Z-score Proportion >95th
percentile
Z-score Proportion >95th
percentile
Heart dimensions
LVEDD [21] 0.28±1.80 31% −1.55±1.55 0% −0.83±1.43 6%
LVESD [21] 0.21±1.75 19% −1.74±1.77 0% −1.46±1.97 12%
SeptD [21] 2.91±1.80 87% 3.17±1.72 80% 3.18±1.17 94%
LVPWD [21] 2.34±1.54 56% 1.79±2.11 60% 2.21±1.45 59%
LV mass-for-height [12]a 0.96±1.65 33% −0.09±1.94 16% −0.07±1.41 18%
Volume indicators
Plasma ANP-N (nmol/L)b 8.9±8.7 2.7±1.2 3.3±1.9
Systolic BP (mmHg)c 105±18 40% 101±20 29% 104±18 37%
Diastolic BP (mmHg)c 56±10 0% 56±14 14% 55±12 11%
All values are given as the mean ± 1 SD
LVEDD, Left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; SeptD, interventricular septal dimension at
end-diastole; LVPWD, left ventricular posterior wall thickness at end-diastole; ANP-N, N-terminal atrial natriuretic peptide; BP, blood pressure
a n=21 at baseline, n=18 at 3 months, and n=17 at 6 months
b n=18 at baseline, n=19 at 3 months, and n=17 at 6 months
c n=20 at baseline, n=21 at 3 months, and n=19 at 6 months
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We reached the target iPTH level in only 30% of our
children, but 70% had a concentration <300 ng/L, and their
calcium, phosphate, and alkaline phosphatase concentra-
tions as well as growth were quite acceptable.
The weekly Kt/V levels for urea, which describe the
clearance of small molecules, were favorable in our patients
throughout the dialysis period. Clearance of the midsized
molecules can be studied by two different methods—the
conventional method, weekly Ccr, and weekly creatinine
Kt/V. Among our patients, the Ccr levels were far lower
than our target level, especially in nephrectomized children,
but these infants still grew well during the dialysis period.
In our earlier studies, the 24-h clearances were 13–15%
higher than with the patients’ normal dialysis program
(used here) due to an additional long dwell as part of the
peritoneal equilibration test [6, 7]. Moreover, it is important
to note that Ccr is related to BSA, which is relatively large
in infants compared with that of older children or adults and
which may explain some of these lower Ccr values. The
method based on weekly creatinine Kt/V was reported by
Ishikura et al. [30] to correlate the clearance of creatinine
with total body water in contrast to BSA. In adult patients
(male; 170 cm, 65 kg), a Ccr level of 60 L/week per 1.73 m
2
corresponds to a weekly creatinine Kt/Vof 1.52 [30]. In our
patients, the mean Ccr was 49±20 L/week per 1.73 m
2 and
the mean creatinine Kt/V was 2.19±0.91. A weekly
creatinine Kt/V value of 1.52 is equivalent to a Ccr level
of 35 L/week per 1.73 m2. The mean weekly Ccr level was
1.92±0.58 in anuric patients and 3.01±1.22 in children
with RRF. Our data suggest that Ccr values as low as 40 L/
week per 1.73 m2 in infants are acceptable for good growth
if the nutrition is optimal and the clinical status and
metabolic control of the patients are favorable. Although
randomized prospective trials would be optimal to definite-
ly answer this question, it is difficult to obtain enough
children, and such studies may be difficult to perform
within an acceptable ethical context.
A total of 57% of our patients had a systolic blood pressure
over the 95th percentile at some point during dialysis; in our
previous study, this percentage was 73% in patients <5 years
of age [5]. Thus, there was less hypertension among the
patients of the present study, but high blood pressure still
remained a problem during PD. Only 10% of our patients
had antihypertensive medication at baseline compared with
55% of the patients at baseline in the above-mentioned
earlier study [5]. At baseline we often observed hypertension
being caused by hypervolemia and were reluctant to begin
antihypertensive medication. Instead, we increased ultrafiltra-
tion to achieve euvolemia. The sodium supplementation used
in most patients could scarcely be considered a cause of
hypertension since plasma sodium values as low as 135mmol/
L were accepted as adequate. In nephrectomized infants, the
best predictors of intravascular volume status in our study
were blood pressure and echocardiography. If the patient has
hypervolemia and is hypertensive, ultrafiltration should be
increased. However, in anuric patients more care is needed in
reacting to high blood pressure values. We also used
bioimpedance analysis (BIA) in our study, but the measure-
ments were technically demanding, and the results were of no
value in estimating intravascular volume status, mainly
because we lacked the normal values for this age group. We
still miss good tools to estimate dry weight and intravascular
volume status in infants. Keeping blood pressure near the
lower normal limit increases the risk for hypovolemia during
vomiting, perspiration, fever, and infections. Severe hypovo-
Fig. 3 Height SDS levels (n=21) in infants at PD start, after
6 months, and at the end of PD (darker bars) compared with their
target height SDS (lighter bar). Median, quartiles, and extreme values
are presented
Fig. 2 Height standard deviation score (SDS) in 21 PD patients
<2 years of age at 6 and 3 months prior to PD initiation, at PD
initiation, and up to the end of PD
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lemia may even cause brain damage [10, 31]. It is therefore
probably safer to allow mild hypervolemia in infants.
A total of 86% of our patients had an LVMI exceeding
the 95th percentile at baseline, compared with 60% of the
patients <5 years of age in our previous study [5]. On the
other hand, using a novel method developed by Foster et
al., which is especially useful for young patients [12], LVH
was found in only 33% of our patients at baseline. During
PD, the proportion of patients with LVH and LVEDD Z-
scores over the 95th percentile decreased, indicating
successful management of intravascular volume status and
hypertension. Plasma ANP-N reflects current intravascular
volume status, while LVM changes only slowly. This is
likely to be the reason why the ANP-N did not correlate
with LVH.
Infants were formerly observed to grow poorly during
PD. More recent reports, however, demonstrate good
growth in this age group [6, 7, 32, 33]. None of these
earlier reports compared gained height with midparental
height. Luo et al. [34] showed that length at birth had a
negative influence on catch-up growth during infancy, but
not thereafter, while parent-specific height had a positive
effect on catch-up growth from the onset of childhood.
Our children had a normal mean height at birth (−0.69
SDS), but although they grew normally for age during
PD, they did not reach their midparental height at about
18–24 months of age because they lost relative height
prior to optimal renal replacement therapy. Their final
height can only be documented when growth has ceased
in young adulthood, and follow-up after renal transplan-
tation will show if these children finally attain their
midparental height, although at a later age than could be
expected.
In conclusion, we have largely been able to optimize
growth and metabolic control during dialysis, mainly due to
optimal food intake in combination with sufficient dialysis
dose, but the time before PD initiation is of the outmost
importance, as shown by the decrease in growth prior to
PD. Even with normal growth during PD, often with catch-
up, midparental height is not attained at the end of infancy.
Thus, we suggest that early diagnoses, sufficient diet, and
metabolic control prior to dialysis are crucial for the long-
term outcome of these children and should improve growth
closer to their parental target height. Several instruments are
needed for intravascular volume status control during PD.
Our patient population was small but very homogenous,
and the results are congruent with previous retrospective
reports.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
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